This story has been updated from a previous version.

NEW YORK, April 11 – Incyte Genomics said Wednesday it had licensed two patents to Merck that will allow the pharmaceutical company to manufacture microarrays using a patented non-PCR method for RNA amplification.

The patents, numbers 5,716,785 and 5,891,636, cover the use of a non-PCR-based RNA amplification technology, allowing researchers to create gene expression information by linearly increasing RNA samples from cellular mRNA.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.